Medical Device CRO Australia

Mobius is a founder-led MedTech contract research organisation (CRO) supporting medical device clinical trial strategy, execution, regulatory-aware evidence planning, and local delivery across Australia, New Zealand, and the United States for startups, sponsors, and global CRO teams.

Schedule a call

Australian medical device trials, planned for global evidence goals

Australia can be a practical place to generate early clinical evidence, but value depends on design, site readiness, documentation, and how well the data fits your wider regulatory pathway. Mobius helps MedTech teams plan and run studies with the discipline expected by sponsors, investigators, ethics committees, and regulators.

Australia

Local CRO delivery for Australian clinical trial planning, site engagement, start-up, monitoring, data, and close-out.

MedTech

Device-specific support for feasibility, first-in-human, pivotal, SaMD, AI medical device, and post-market evidence programs.

Global

Evidence planning connected to ISO 14155, ICH GCP, TGA, FDA, EU, and sponsor quality expectations where applicable.

Why Australia for medical device clinical trials?

Australia is often considered for early feasibility, first-in-human, pilot, and selected pivotal medical device studies because the clinical trial environment is established, ethics-led, and familiar to global MedTech teams.

The opportunity is not simply speed. It is the ability to build credible clinical evidence in a system that expects strong protocol design, clear risk management, trained sites, and reliable data.

For studies involving unapproved therapeutic goods, Australia has CTN and CTA pathways. These pathways are not interchangeable, and CTN should not be treated as TGA approval. The right pathway depends on the device, risk profile, prior evidence, and study context.

A CRO built around MedTech, not pharma templates

Medical device trials are different. They can involve procedure learning curves, investigator training, usability considerations, device iteration, imaging or performance endpoints, and close coordination between engineering, clinical, and regulatory teams.

Mobius brings a medical device CRO model to that complexity. We help sponsors make practical decisions without losing the rigour needed for downstream submissions, investor confidence, and clinical adoption.

Clinical strategy before study start-up

The strongest Australian study is designed with the end in mind. We help define the clinical question, patient population, endpoint structure, comparator logic, site profile, monitoring approach, and evidence package before study start-up begins.

That means fewer late surprises and a clearer line between the study you can run now and the regulatory, reimbursement, or investor milestone you need next.

Explore medical device clinical trial strategy

Get in touch ->

How Mobius supports medical device sponsors in Australia

Work with us end-to-end, or use Mobius as a focused Australian delivery partner backed by operations across Australia, New Zealand, and the United States.

Strategy and feasibility. Clinical question, endpoint logic, site profile, patient population, risk controls, budget planning, and evidence pathway alignment.

Australian start-up. Site selection, investigator engagement, ethics and governance documentation, vendor coordination, and study activation planning.

Trial execution. Project management, monitoring, safety processes, data management oversight, study close-out, and inspection-ready documentation.

Regulatory-aware evidence. Planning that considers HREC, TGA, ISO 14155, ICH GCP, ARTG, FDA, EU, and sponsor quality expectations where relevant.

Device trial pathways we support

Founders may need an efficient first clinical study that strengthens fundraising and de-risks development. Clinical affairs leaders may need clean local execution. Global CROs may need an experienced regional partner. Mobius adapts the model to the job across Australia, New Zealand, and the United States.

First-in-human and early feasibility

Plan an evidence-generating first clinical step with clear risk controls, investigator training, and a pathway to the next development milestone.

Pivotal and expansion studies

Build operationally realistic studies with site engagement, monitoring, data integrity, and documentation expectations considered from the outset.

SaMD, AI, and post-market evidence

Support clinical evidence planning for software, AI-enabled devices, diagnostics, usability questions, and post-market evidence needs.

Regulatory and ethics considerations in Australia

All Australian clinical trials require appropriate ethics review. For unapproved therapeutic goods, CTN and CTA pathways may also be relevant. CTN is a notification scheme that relies on Human Research Ethics Committee review and sponsor responsibility; CTA involves TGA review of limited scientific data before the trial proceeds.

For international sponsors, local arrangements matter. Trial sponsorship, HREC documentation, governance, insurance, safety reporting, investigator training, monitoring, and data standards all need to be aligned before recruitment begins.

Mobius helps teams prepare carefully. We do not treat Australian data as a shortcut. We treat it as part of a deliberate evidence strategy that may support later TGA, FDA, EU, reimbursement, or investor-facing decisions when designed appropriately.

Evidence that can travel

Clinical data only travels when the study is well designed, well conducted, and documented to the standards expected by the receiving regulator or stakeholder.

We help teams think early about ISO 14155, ICH GCP, monitoring, data integrity, safety reporting, clinical investigation reports, and submission usability so Australian trial activity is connected to the larger evidence plan.

Explore regulatory strategy and clinical evidence support

Browse Mobius clinical trial resources

Clinical trial execution ->

Relevant medical device experience

Use our case studies to see how Mobius supports medical device teams across feasibility, pivotal, AI, interventional, and patient-centred evidence programs.

AI-powered skin cancer detection

FIH

Mitral valve innovation from early feasibility to pivotal study

Pivotal

World-first aspiration thrombectomy trial

Patient

Non-invasive pain relief device for pregnancy

See case studies ->

Questions sponsors ask about Australian medical device trials

Short answers for MedTech teams evaluating Australia as part of a clinical evidence pathway.

Can a US company run a medical device trial in Australia?

Yes, but Australian clinical trials require appropriate local arrangements, including an Australian trial sponsor entity where applicable. Mobius can help international teams understand the operational and documentation requirements and plan the right local model.

Are Australian medical device trial data accepted by FDA?

FDA can accept data from clinical investigations conducted outside the United States when the investigation is well designed, well conducted, and meets applicable requirements. This should be planned deliberately rather than assumed.

Is CTN always the right pathway for a medical device study in Australia?

No. Many studies involving unapproved therapeutic goods use CTN, but some higher-risk or novel device studies may require or benefit from CTA consideration. The pathway should be assessed against the device, evidence base, risk profile, and trial design.

Why use a specialist medical device CRO instead of a general CRO?

Device trials often depend on procedure workflow, investigator technique, training, usability, engineering context, and performance endpoints. A specialist MedTech CRO is better positioned to identify those risks early and build them into the study plan.

Can Australian trial costs qualify for R&D incentives?

Some eligible R&D activities in Australia may qualify for the R&D Tax Incentive, subject to entity eligibility, activity registration, and tax advice. Sponsors should treat this as a specialist tax question, not a guaranteed rebate.

See all FAQs ->

Official references for Australian trial planning

These resources are useful starting points when assessing clinical trial pathway assumptions. They do not replace study-specific regulatory, ethics, legal, or tax advice.

Build your Australian trial pathway with confidence

Talk with Mobius about your device, evidence goals, and the most practical next step for clinical trial planning or execution across Australia, New Zealand, and the United States.

Schedule A Call